As a Liraglutide goes by the following brand names: Saxenda (liraglutide 3.0 mg daily subcutaneous injection) is the only brand with FDA approval for chronic weight management in the adults with obesity adults with overweight and at least one weight-related health condition A Tirzepatide Tirzepatide activates GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP), an intestinal hormone that In 2023, the adults with obesity adults with overweight and at least one weight-related condition Zepbound is both a GLP-1 receptor agonist and a GIP receptor agonist, so it helps reduce appetite and food intake

2 However, patients may face issues with these medications, such as: 2 Weight-related stigma and bias Absence of generic versions for the most effective GLP-1s Availability issues due to medication shortages Lack of coverage by many insurance plans Cost of up to $1,049/month (based on average pricing* of one-month supply of 15 mg Zepbound) 3 Patients who do have insurance coverage for GLP-1s may be overwhelmed by complex prior authorization procedures and high out-of-pocket costs
However, microdosing may prevent you from reaching the effective dose needed to make significant changes in your body weight or blood sugar levels
The more granular approach allows for finer dose titration but takes longer to reach maintenance levels
Insert the needle through the rubber stopper at a slight angle so the needle tip contacts the inside glass wall of the vialnot the lyophilised peptide powder at the bottom
Its still important to follow a healthy eating pattern, such as a diabetic diet meal plan if you have type 2 diabetes, and limit certain foods if you are on a semaglutide medication